Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects
Highlights • TKIs against targetable mutations are highly effective in the metastatic setting. • There is much interest in the role of TKIs in the adjuvant setting to improve survival rate. • The use of TKIs in the adjuvant setting remains experimental and controversial. • Many trials involving TKIs...
Gespeichert in:
| Veröffentlicht in: | Lung cancer (Amsterdam, Netherlands) Netherlands), 2015-10, Vol.90 (1), p.1-7 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 7 |
|---|---|
| container_issue | 1 |
| container_start_page | 1 |
| container_title | Lung cancer (Amsterdam, Netherlands) |
| container_volume | 90 |
| creator | Chuang, Jody C Neal, Joel W Niu, Xiao-Min Wakelee, Heather A |
| description | Highlights • TKIs against targetable mutations are highly effective in the metastatic setting. • There is much interest in the role of TKIs in the adjuvant setting to improve survival rate. • The use of TKIs in the adjuvant setting remains experimental and controversial. • Many trials involving TKIs in the adjuvant settings are ongoing worldwide. |
| doi_str_mv | 10.1016/j.lungcan.2015.07.016 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1710656656</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0169500215300222</els_id><sourcerecordid>1710656656</sourcerecordid><originalsourceid>FETCH-LOGICAL-c490t-2d0c59027d41fdd3d3170a480322c9063c8385c54dccf7b200514558c76b516f3</originalsourceid><addsrcrecordid>eNqFkctu1DAUhi1ERYfCI4CyZJP02I7jhAVoFPUmRiBR2LCxPLYDDpkk9WWkeXscZsqCTSXLln7_5_YdhN5gKDDg6rIvhjj-VHIsCGBWAC-S-gytcM1JXlNKnqNVUpqcAZBz9NL7HgBzDM0LdE4qwlnJqxX6sdZ93MsxZOGXcXI-ZN3ksqub66_ZLoZFl6PO1ptP2Tx5G-zeZJ_v2037Pmujcyb9axnkX1MXQ3Qmm93kZ6OCf4XOOjl48_r0XqDv11ff2tt88-Xmrl1vclU2EHKiQbEGCNcl7rSmmmIOsqyBEqIaqKiqac0UK7VSHd8SAIZLxmrFqy3DVUcv0Ltj3lT5IRofxM56ZYZBjmaKXixDV6xKJ1nZ0apSk96ZTszO7qQ7CAxiwSp6ccIqFqwCuEhqint7KhG3O6P_RT1yTIaPR4NJg-6tccIra0ZltHWJhdCTfbLEh_8yqMGOVsnhtzkY30_RjYmiwMITAeJ-2e2yWsxougmhfwBEjJ5d</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1710656656</pqid></control><display><type>article</type><title>Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Chuang, Jody C ; Neal, Joel W ; Niu, Xiao-Min ; Wakelee, Heather A</creator><creatorcontrib>Chuang, Jody C ; Neal, Joel W ; Niu, Xiao-Min ; Wakelee, Heather A</creatorcontrib><description>Highlights • TKIs against targetable mutations are highly effective in the metastatic setting. • There is much interest in the role of TKIs in the adjuvant setting to improve survival rate. • The use of TKIs in the adjuvant setting remains experimental and controversial. • Many trials involving TKIs in the adjuvant settings are ongoing worldwide.</description><identifier>ISSN: 0169-5002</identifier><identifier>EISSN: 1872-8332</identifier><identifier>DOI: 10.1016/j.lungcan.2015.07.016</identifier><identifier>PMID: 26275476</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Adjuvant ; Anaplastic lymphoma kinase (ALK) ; Antineoplastic Agents - therapeutic use ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - enzymology ; Carcinoma, Non-Small-Cell Lung - genetics ; Carcinoma, Non-Small-Cell Lung - pathology ; Chemotherapy, Adjuvant ; Epidermal growth factor receptor (EGFR) ; Hematology, Oncology and Palliative Medicine ; Humans ; Lung Neoplasms - drug therapy ; Lung Neoplasms - enzymology ; Lung Neoplasms - genetics ; Lung Neoplasms - pathology ; Mutation ; Non-small cell lung cancer (NSCLC) ; Protein Kinase Inhibitors - therapeutic use ; Pulmonary/Respiratory ; Randomized Controlled Trials as Topic ; Receptor Protein-Tyrosine Kinases - antagonists & inhibitors ; Receptor Protein-Tyrosine Kinases - genetics ; Receptor, Epidermal Growth Factor - antagonists & inhibitors ; Receptor, Epidermal Growth Factor - genetics ; Tyrosine kinase inhibitors (TKI)</subject><ispartof>Lung cancer (Amsterdam, Netherlands), 2015-10, Vol.90 (1), p.1-7</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2015 Elsevier Ireland Ltd</rights><rights>Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c490t-2d0c59027d41fdd3d3170a480322c9063c8385c54dccf7b200514558c76b516f3</citedby><cites>FETCH-LOGICAL-c490t-2d0c59027d41fdd3d3170a480322c9063c8385c54dccf7b200514558c76b516f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.lungcan.2015.07.016$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27907,27908,45978</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26275476$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chuang, Jody C</creatorcontrib><creatorcontrib>Neal, Joel W</creatorcontrib><creatorcontrib>Niu, Xiao-Min</creatorcontrib><creatorcontrib>Wakelee, Heather A</creatorcontrib><title>Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects</title><title>Lung cancer (Amsterdam, Netherlands)</title><addtitle>Lung Cancer</addtitle><description>Highlights • TKIs against targetable mutations are highly effective in the metastatic setting. • There is much interest in the role of TKIs in the adjuvant setting to improve survival rate. • The use of TKIs in the adjuvant setting remains experimental and controversial. • Many trials involving TKIs in the adjuvant settings are ongoing worldwide.</description><subject>Adjuvant</subject><subject>Anaplastic lymphoma kinase (ALK)</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - enzymology</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Chemotherapy, Adjuvant</subject><subject>Epidermal growth factor receptor (EGFR)</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - enzymology</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - pathology</subject><subject>Mutation</subject><subject>Non-small cell lung cancer (NSCLC)</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Pulmonary/Respiratory</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Receptor Protein-Tyrosine Kinases - antagonists & inhibitors</subject><subject>Receptor Protein-Tyrosine Kinases - genetics</subject><subject>Receptor, Epidermal Growth Factor - antagonists & inhibitors</subject><subject>Receptor, Epidermal Growth Factor - genetics</subject><subject>Tyrosine kinase inhibitors (TKI)</subject><issn>0169-5002</issn><issn>1872-8332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkctu1DAUhi1ERYfCI4CyZJP02I7jhAVoFPUmRiBR2LCxPLYDDpkk9WWkeXscZsqCTSXLln7_5_YdhN5gKDDg6rIvhjj-VHIsCGBWAC-S-gytcM1JXlNKnqNVUpqcAZBz9NL7HgBzDM0LdE4qwlnJqxX6sdZ93MsxZOGXcXI-ZN3ksqub66_ZLoZFl6PO1ptP2Tx5G-zeZJ_v2037Pmujcyb9axnkX1MXQ3Qmm93kZ6OCf4XOOjl48_r0XqDv11ff2tt88-Xmrl1vclU2EHKiQbEGCNcl7rSmmmIOsqyBEqIaqKiqac0UK7VSHd8SAIZLxmrFqy3DVUcv0Ltj3lT5IRofxM56ZYZBjmaKXixDV6xKJ1nZ0apSk96ZTszO7qQ7CAxiwSp6ccIqFqwCuEhqint7KhG3O6P_RT1yTIaPR4NJg-6tccIra0ZltHWJhdCTfbLEh_8yqMGOVsnhtzkY30_RjYmiwMITAeJ-2e2yWsxougmhfwBEjJ5d</recordid><startdate>20151001</startdate><enddate>20151001</enddate><creator>Chuang, Jody C</creator><creator>Neal, Joel W</creator><creator>Niu, Xiao-Min</creator><creator>Wakelee, Heather A</creator><general>Elsevier Ireland Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20151001</creationdate><title>Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects</title><author>Chuang, Jody C ; Neal, Joel W ; Niu, Xiao-Min ; Wakelee, Heather A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c490t-2d0c59027d41fdd3d3170a480322c9063c8385c54dccf7b200514558c76b516f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adjuvant</topic><topic>Anaplastic lymphoma kinase (ALK)</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - enzymology</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Chemotherapy, Adjuvant</topic><topic>Epidermal growth factor receptor (EGFR)</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - enzymology</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - pathology</topic><topic>Mutation</topic><topic>Non-small cell lung cancer (NSCLC)</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Pulmonary/Respiratory</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Receptor Protein-Tyrosine Kinases - antagonists & inhibitors</topic><topic>Receptor Protein-Tyrosine Kinases - genetics</topic><topic>Receptor, Epidermal Growth Factor - antagonists & inhibitors</topic><topic>Receptor, Epidermal Growth Factor - genetics</topic><topic>Tyrosine kinase inhibitors (TKI)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chuang, Jody C</creatorcontrib><creatorcontrib>Neal, Joel W</creatorcontrib><creatorcontrib>Niu, Xiao-Min</creatorcontrib><creatorcontrib>Wakelee, Heather A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chuang, Jody C</au><au>Neal, Joel W</au><au>Niu, Xiao-Min</au><au>Wakelee, Heather A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects</atitle><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle><addtitle>Lung Cancer</addtitle><date>2015-10-01</date><risdate>2015</risdate><volume>90</volume><issue>1</issue><spage>1</spage><epage>7</epage><pages>1-7</pages><issn>0169-5002</issn><eissn>1872-8332</eissn><abstract>Highlights • TKIs against targetable mutations are highly effective in the metastatic setting. • There is much interest in the role of TKIs in the adjuvant setting to improve survival rate. • The use of TKIs in the adjuvant setting remains experimental and controversial. • Many trials involving TKIs in the adjuvant settings are ongoing worldwide.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>26275476</pmid><doi>10.1016/j.lungcan.2015.07.016</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0169-5002 |
| ispartof | Lung cancer (Amsterdam, Netherlands), 2015-10, Vol.90 (1), p.1-7 |
| issn | 0169-5002 1872-8332 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1710656656 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adjuvant Anaplastic lymphoma kinase (ALK) Antineoplastic Agents - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - enzymology Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Chemotherapy, Adjuvant Epidermal growth factor receptor (EGFR) Hematology, Oncology and Palliative Medicine Humans Lung Neoplasms - drug therapy Lung Neoplasms - enzymology Lung Neoplasms - genetics Lung Neoplasms - pathology Mutation Non-small cell lung cancer (NSCLC) Protein Kinase Inhibitors - therapeutic use Pulmonary/Respiratory Randomized Controlled Trials as Topic Receptor Protein-Tyrosine Kinases - antagonists & inhibitors Receptor Protein-Tyrosine Kinases - genetics Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - genetics Tyrosine kinase inhibitors (TKI) |
| title | Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T18%3A34%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adjuvant%20therapy%20for%20EGFR%20mutant%20and%20ALK%20positive%20NSCLC:%20Current%20data%20and%20future%20prospects&rft.jtitle=Lung%20cancer%20(Amsterdam,%20Netherlands)&rft.au=Chuang,%20Jody%20C&rft.date=2015-10-01&rft.volume=90&rft.issue=1&rft.spage=1&rft.epage=7&rft.pages=1-7&rft.issn=0169-5002&rft.eissn=1872-8332&rft_id=info:doi/10.1016/j.lungcan.2015.07.016&rft_dat=%3Cproquest_cross%3E1710656656%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1710656656&rft_id=info:pmid/26275476&rft_els_id=1_s2_0_S0169500215300222&rfr_iscdi=true |